Daniel Barber - 08 Sep 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: President and CEO, Director
Issuer ticker: AQST
Reported as of: 08 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2026, 17:10:52 UTC
Prior SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Zalewski, as Attorney-In-Fact

Key filing fact

Daniel Barber filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 09 Sep 2026.

Key facts

This page summarizes Daniel Barber's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Sep 2026, 17:10.

Change

Previous filing in this sequence was filed on 18 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742266 Primary reporting owner

Barber Daniel

Relationship: President and CEO, Director
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Thomas Zalewski, as Attorney-In-Fact
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +91,743
Change %: +16%
Price: $0.9600^*
Shares after: 677,317
Date: 08 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Warrant (Right to Buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -91,743
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 08 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 91,743
Exercise price: $0.9600

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.